|Bid||0.00 x 1100|
|Ask||0.00 x 1100|
|Day's Range||12.63 - 13.47|
|52 Week Range||6.51 - 37.99|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 01, 2022 - Aug 05, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.78|
WALTHAM, Mass., June 16, 2022--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings 20 years of life science leadership experience to the role, and her responsibilities will include developing and leading the Company’s business development efforts as well as supporting corporate strategy initiatives.
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.